Dogwood Therapeutics Inc Ordinary Shares DWTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.50
- Day Range
- $1.50–1.56
- 52-Week Range
- $1.29–9.49
- Bid/Ask
- $1.11 / $1.74
- Shares Outstanding
- 33.63M
- Market Cap
- $50.11M
- Volume/Avg
- 25,549 / 105,463
Key Statistics
- Price/Earnings (Normalized)
- 2.80
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.virios.com
Valuation
|
Metric
|
DWTX
|
|---|---|
Price/Earnings (Normalized) | 2.80 |
Price/Book Value | 0.64 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
DWTX
Financial Strength
|
Metric
|
DWTX
|
|---|---|
Quick Ratio | 5.17 |
Current Ratio | 5.86 |
Interest Coverage | — |
Quick Ratio
DWTX
Profitability
|
Metric
|
DWTX
|
|---|---|
Return on Assets (Normalized) | −29.43% |
Return on Equity (Normalized) | −160.41% |
Return on Invested Capital (Normalized) | −35.06% |
Return on Assets
DWTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Affymax Inc
AFFY
| — | Mpxp | — | |||
| Athersys Inc
ATHXQ
| — | Zcnxf | — | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xfxymhmlf | Jqwpfv | $116B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rqbfdybbw | Hjvzyh | $64B | |||
| argenx SE
ARGNF
| — | Qbbk | $56B | |||
| argenx SE ADR
ARGX
| Tcprwlbh | Bsf | $56B | |||
| UCB SA
UCBJF
| — | Rfwbr | $56B | |||
| UCB SA ADR
UCBJY
| — | Bdkyy | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vffyccpd | Zrkvlgy | $38B | |||
| CSL Ltd
CMXHF
| — | Gyrhsd | $36B |
United States